Drugs / pbi-shRNA STMN1 LP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01505153 | Feb 2012 → Mar 2017 | metastatic malignant neoplasm | Gradalis, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pbi-shRNA STMN1 LP | “This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single...” NCT01505153 ↗ |
| Known as | pbi-shRNASTMN1 | “This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single...” NCT01505153 ↗ |
| Modality | Oligonucleotide (other) | “bifunctional shRNA-STMN1 (pbi-shRNA™STMN1)” NCT01505153 ↗ |
| Route | Other | “single intratumoral (IT) injection” NCT01505153 ↗ |